99mTc-EDDA/HYNIC-TOC and 18F-FDG in thyroid cancer patients with negative 131I whole-body scans

This publication has 38 references indexed in Scilit:

• Clinical impact of (18)F-FDG PET in thyroid carcinoma patients with elevated thyroglobulin levels and negative (131)I scanning results after therapy.
  2001
• Procedure guideline for somatostatin receptor scintigraphy with (111)In-pentetreotide.
  2001
• Radiopeptide transmitted internal irradiation of non-iodophil thyroid cancer and conventionally untreatable medullary thyroid cancer using [90Y]-DOTA-D-Phe1-Tyr3-octreotide: a pilot study
  Nuclear Medicine Communications, 2001
• Somatostatin receptor scintigraphy in the follow-up of patients with differentiated thyroid cancer
  Journal of Endocrinological Investigation, 2001
• Peptide receptor imaging and therapy.
  2000
• 99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours: first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives
  European Journal of Nuclear Medicine and Molecular Imaging, 2000
• The relevance of somatostatin receptors in thyroid neoplasia.
  1998
• Use of indium-111 pentetreotide somatostatin receptor scintigraphy to detect recurrent thyroid carcinoma in patients without detectable iodine uptake
  European Journal of Nuclear Medicine and Molecular Imaging, 1998
• Somatostatin receptor expression in Hürthle cell cancer of the thyroid.
  1998
• Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients
  European Journal of Nuclear Medicine and Molecular Imaging, 1993